Comparably, the induction of Bip and consistent rise in CHOP expression was observed in all prostate cancer cells during dose-dependent treatments of TA, which was further affirmed from potential studies at both gene and protein levels (Figure 2A,B). Here, DDIT3 is linked to prostate cancer.